Essential oil from the leaves of Eugenia pohliana DC. (Myrtaceae) alleviate nociception and acute inflammation in mice

• Published in: Inflammopharmacology Vol. 30; no. 6; pp. 2273 - 2284
• Main Authors: do Nascimento, Andreza Larissa, Guedes, Joyce Bezerra, Costa, Wêndeo Kennedy, de Veras, Bruno Oliveira, de Aguiar, Júlio César Ribeiro de Oliveira Farias, Navarro, Daniela Maria do Amaral Ferraz, Correia, Maria Tereza dos Santos, Napoleão, Thiago Henrique, de Oliveira, Alisson Macário, da Silva, Márcia Vanusa
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.12.2022
• Subjects: Allergology; Biomedical and Life Sciences; Biomedicine; Dermatology; Gastroenterology; Immunology; Original Article; Pharmacology/Toxicology; Rheumatology; β (E)-caryophyllene; Analgesic; Caatinga; Anti-inflammatory
• ISSN: 0925-4692; 1568-5608
• DOI: 10.1007/s10787-022-01067-y

Eugenia pohliana DC.(Myrtaceae) is used in folk medicine by communities in Brazil. However, there are no reports on its biological activity. This is the first study to identify the components of E. pohliana essential oil (EpEO) and evaluate their antinociceptive and anti-inflammatory activities in an in vivo model at doses of 25, 50, and 100 mg/kg. The essential oil (EO) was obtained by hydrodistillation, and the analysis was performed by gas chromatography coupled with mass spectrometry. Antinociceptive activity was evaluated by writhing tests, tail movement, and formalin (neurogenic and inflammatory pain); naloxone was used to determine the nociception mechanism. Anti-inflammatory activity was assessed by oedema and peritonitis tests. We found that (E)-β-caryophyllene (BCP) (15.56%), δ-cadinene (11.24%) and α-cadinol (10.89%) were the major components. In the writhing test, there was a decrease in writing by 42.95–70.70%, in the tail movement, an increase in latency time by 69.12–86.63%, and in the formalin test, there was a reduction in pain neurogenic by 29.54–61.74%, and inflammatory pain by 37.42–64.87%. The antinociceptive effect of EpEO occurs through the activation of opioid receptors. In addition, a reduction in inflammation by 74.93‒81.41% was observed in the paw edema test and inhibition of the influx of leukocytes by 51.86‒70.38% and neutrophils by 37.74‒54.72% in the peritonitis test. It was concluded that EpEO has antinociceptive effect by the opioid pathway, as shown by the inhibitory effect of naloxone, and anti-inflammatory actions, and that its use does not cause hemolytic damage or behavioral change.